|Articles|August 31, 2006
Aida Pharmaceuticals Acquires Majority Stake in Shanghai Qiaer Bio-Technology
Author(s)BioPharm International Editors
Aida Pharmaceuticals (Hangzhou, China) has completed its acquisition of majority control of Shanghai Qiaer Bio-Technology Co., Ltd (Shanghai, China).
Advertisement
Aida Pharmaceuticals (Hangzhou, China) has completed its acquisition of majority control of Shanghai Qiaer Bio-Technology Co., Ltd (Shanghai, China). Qiaer Bio-Technology’s flagship drug, Rh-Apo2L, a gene drug developed to treat various forms of cancer, just completed Phase 1 clinical trials.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5
